Amgen Completes Acquisition of Alantos

19-Jul-2007

Amgen announced the completion of its acquisition of Alantos, a private company developing drugs for the treatment of diabetes and inflammatory diseases. The transaction provides Amgen with Alantos's DPP-IV inhibitor in clinical development (Phase 2a) for the treatment of type II diabetes as well as its matrix metalloproteinases platform for osteoarthritis. The acquisition was originally announced June 6.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...